Abstract. We analyze the influence of technological progress on pharmaceuticals on rising health expenditures using US State level panel data. Improvements in medical technology are believed to be partly responsible for rapidly rising health expenditures. Even if the technological progress in medicine improves health outcomes and life quality, it can also increase the expenditure on health care. Our findings suggest that newer drugs increase the spending on prescription drugs since they are usually more expensive than their predecessors. However, they lower the demand for other types of medical services, which causes the total spending to decline. A one-year decrease in the average age of prescribed drugs causes per capita health expenditures to decrease by $31.92. The biggest decline occurs in spending on hospital and home health care due to newer drugs.
Introduction
In most developed countries, there has been a rising trend in health expenditures. The growth rates of the health expenditures are generally higher than the growth of the overall economy. As a result, the ratio of the health expenditure to the GDP has been rising continuously. The percentage of health expenditures in the GDP was 3.8% in 1960 for OECD countries and has been continuously increasing since then.
1 . The trends in US and in most other countries have been similar. In the US, the ratio of health expenditures to the GDP rose This significant variation in health care spending begs an explanation. Different societies might have different demand levels for health services or might have diverse health care "needs" due to the differences in life style, environmental conditions, or genetic characteristics. Alternatively, perhaps health care systems are not managed as efficiently as possible everywhere. Health care markets are poised with numerous problems such as moral hazard, principal-agent problems, and information failures. Any of these problems can cause markets to operate inefficiently. When we look at the details of the health care spending, we see that the inefficient management of health care systems is highly possible. For example, pharmaceutical spending makes up only 9.4% of the total health expenditure in Norway, while the same figure is 29.4% in Poland. Even if the variation in input choice for the health care (production function) does not mean inefficiency per se, the size of this variation raises a question mark. Indeed Baicker and Sandar (2004) and Fisher et al (2003a Fisher et al ( , 2003b conclude that higher spending in health care does not improve health outcomes or patient satisfaction level. Thus, academics and policy makers have been analyzing the health care markets and trying to understand the driving factors behind the continuing increase in health expenditures for decades. In this paper, we contribute to the literature by analyzing the influence of technological improvement in pharmaceutical markets on health spending levels using panel data for US States.
1 The ratios of the health expenditures to the GDP for 1970 GDP for , 1980 GDP for , 1990 GDP for , 2000 GDP for and 2004 .9%, and 9.0%, respectively. These numbers are un-weighted averages of current OECD member countries 2 See OECD Health Data 2007. 3 See Table 1 .
The rest of the paper is organized as follows: In section 2, we discuss some background information and previous literature about the rising health expenditures. Section 3 summarizes the significance of pharmaceuticals on medical markets and on rising health expenditures. Sections 4 and 5 present the data and empirical methodology, respectively. We discuss the results in Section 6 and conclude in section 7.
Rise in Health Expenditures and New Technologies
Several explanations for the rising health expenditures have been cited in the health economics literature. Primary explanation is the rising incomes. Wealthier individuals are willing to pay more for their health, i.e. health care is a normal good. An increasing amount of spending on health care is a natural result of economic growth. Almost all studies analyzing the health care costs found a positive relationship between per capita income and health spending. 4 In fact, earlier studies conclude that income differences can explain almost all of the variation in the spending levels. Another reason for rising health spending is the aging societies. Generally old and very old require much more health care than young and middleaged. Many studies use the percentage of population over 65 as a proxy for this demographic shift. Most studies have concluded that aging societies are spending more on health services 5 .
Insurance coverage is another explanation cited in the literature. As it is common in many markets, insurance coverage can cause moral hazard problems. The individuals, who do not pay for the whole costs of the services they get, tend to use more health care than the efficient level. However, insurance firms are also better equipped than individual patients against the health care suppliers. Specifically, they can use their market power to get favorable terms because they can buy health services in bulk. Moreover, they can take much stronger measures than the individual patients against the advantages of the suppliers due to asymmetric information.
However, rising income levels, demographic shift and increased insurance coverage can only explain a relatively small portion of the rise in health expenditures. Slade and Anderson (2001) note that there is nearly a consensus among health economists that a substantial portion of the increase in health care spending is due to diffusion of new medical technologies. According to Newhouse (1992) , usual suspects (supplier induced demand, aging population, income growth, increased insurance) can explain approximately half of the rise in the health expenditures. He conjectures that the rest of the increase should be given to 4 See Gerdtham and Jonsson (2000) for a good review. 5 See for example Gerdtham and et all (1992) technological improvement in health services. Cutler et al. (1998) 
Pharmaceuticals
Pharmaceuticals have been getting more attention than other types of medical services for a number of reasons. First, the share of pharmaceutical spending on the total health expenditures has been rising in the US and in many other OECD countries since 1980s. In the US, the share of pharmaceutical drugs increased from historical lows of 8.7% in 1982 to 12.4% in 2005. Similarly, the share of pharmaceuticals on public agencies' budgets has been increasing. Duggan and Evans (2007) suggest that new drugs not only lower the mortality rate by 68% but they also decrease the short-term health care spending by reducing expenditures on other categories of medical care.
The average lifetime Medicaid spending on AIDS patients has increased from $89,000 to 7 We do not claim that the drug companies are monopolies in technical sense. We mean that there is such a perception. 8 Grabowski and et. all (2002) showed that is not the case.
$234,000, however, because AIDS patients live longer and require more medical care in the long run.
Lichtenberg has published a series of articles on the values of new drugs using various data sources and methodologies. His studies confirm the proposition that new drugs are not only useful in terms of better health outcomes but they also lower the health expenditures. Lichtenberg (1996) Generally, patient/event/disease level data are used in the previous studies. These studies try to control for the endogeneity of the drug use. Generally, newer drugs are first prescribed and used on the patients who are relatively sicker than the average patient. New Mexico has the lowest private insurance coverage with 57% and Iowa has the highest with 82%. Average of government insurance coverage in US States is 26%.
Empirical Methodology
We estimate the following panel-data models: We estimate equations (1) and (2) by using the fixed effects regression methods and report the heteroskedasticity-robust standard errors obtained by using the Huber-White sandwich estimator. Using AR1 or panel-specific AR1 autocorrelation structure produces qualitatively and quantitatively similar results.
Results and Discussion
The focus of this study is the influence of innovation in pharmaceutical sector on health spending. As we have discussed earlier, we use the average drug age prescribed in each region as a proxy for the diffusion of new technologies. The presumption is that the smaller the value of "drug age" the higher the technological level of the pharmaceutical products.
First column of Table 2 reports the estimation results for the effect of drug age on per capita total health expenditures. The positive and statistically significant coefficient of the variable "drug age" suggests that the newer the drugs prescribed in a state are, the lower the total per capita health spending in that state. This implies that newer drugs not only increase the quality of medical care but also actually lower the total health expenditures. Usually newer drugs have lower side effects, thus patients would be willing to pay more for them.
Moreover, due to treatment expansion effects, newer drugs would expand the potential patient 19 Levin, Lin, and Chu (2002) pool. Naturally, as the number of patients to be treated increases, the total treatment costs also increases. However, similar to the results found in the literature that we have discussed earlier, our findings imply that the newer medicines are so effective that even if there are more patients to be treated and each patient is willing to pay more for the lower side effects, the total spending decreases. However, earlier studies generally use individual and/or event level data; therefore, they do not consider the treatment expansion effects. Since we use aggregate state level data, our results are stronger. As an example, a one-year decrease in the average age of prescribed drugs causes per capita health expenditures to decrease by $31.92. This amounts to a significant reduction of $171,974,723 for an average state population of 5,387,038 for our sample period.
The estimated coefficients of other exogenous variables are generally inline with the prior expectations. The positive coefficient on per capita income suggests that on average, patients of wealthier states spent more on health care because they are willing and able to do so. In addition, sickness or death is costlier for them than the residents of lower income states due to working productivity differences. Indeed, the positive relationship between income and health spending is a common result found in the health expenditure literature.
Interestingly, we find a positive (negative) relationship between the percentage of government (private) insurance coverage and the HCE. One possible reason is that the cost containment strategies of private insurance firms are more successful than that of the public agencies. However, it is also possible that the private insurance companies select the relatively low cost patients, and government insurance is generally for the poor and old who have a higher possibility of getting sick and who need more medical care. demographic variable that we employ, which is the percentage of population over 65.
In the second column of the Table 2 , the health expenditures on pharmaceutical drugs is the dependent variable. As expected, relatively newer drugs cost more. The negative coefficient of "drug age" indicates that the states in which relatively newer drugs are prescribed spent more on pharmaceuticals. This result is parallel to the earlier studies. Newer drugs are more expensive than older ones. A one-year decrease in the average age of prescribed drugs causes the per capita health expenditures on pharmaceutical drugs to increase by $6.4.
On the third column of Table 2 , non-drug health expenditures is the dependent variable. The hypothesis we test in this regression is that the newer drugs save money since they lower the expenditures on other types of medical services like physician services, hospital stays, and surgical operations. The positive coefficient of drug age implies that the data confirm our hypothesis. Higher technology (newer) drugs are more effective than the relatively older ones, which cause the patients who take them to utilize other types of medical services less. Table 5 . Newer drugs reduce hospital care and home health care expenditures while increasing non-durable medical products spending. In addition, newer pharmaceutical products also lower the expenditure on durable medical products in the short run.
Conclusion
In this paper, we studied the influence of the technological improvement in pharmaceutical technology on health care spending using US State level panel data. We find that even if newer drugs are more expensive than their predecessors, they are much more effective so that they reduce total health expenditures by lowering the need for other types of medical services.
Earlier studies on the subject have not analyzed the treatment expansion effects, i.e., the ability to treat hitherto untreatable patients, of the new drugs. Treatment expansion effects almost certainly would increase the total health expenditures unlike the treatment substitution effects. Some of the earlier studies found that newer drugs lower the per patient health expenditures. However, many new drugs also expand the potential patient pool. Thus in theory, even if new drugs lower per patient expenditures they could increase the total health expenditures in a state by treating hitherto untreatable patients. However, our results indicate that is not the case for US States. By using aggregate data, we show that the newer drugs lower total health expenditures in a state.
Although most health economists believe that the rising trend in health spending is partly due to improvement in health technologies, many studies including ours conclude that the technological improvement in pharmaceutical products does not rise the health spending but reduces it. This apparent controversy needs an explanation. Many studies have shown that input use in health production is not efficient everywhere. Fisher et al (2003a Fisher et al ( , 2003b conclude that high spending differences between states are almost entirely due to greater frequency of physician visits, more frequent use of specialist consultations, more frequent tests and minor procedures, and greater use of the hospital and intensive care unit. Moreover, they also conclude that the pattern of practice observed in higher-spending regions does not result in improved survival, slower decline in functional status, or improved satisfaction with care. These conclusions imply that high spending regions use wrong types of technologically advanced medical goods and services, since the government officials play a significant role in planning of the medical markets.
Our results suggest that regulatory and reimbursement policies toward technologically better medical goods and services should be reconsidered, and usage of newer drugs should be encouraged more than usage of newer versions of non-pharmaceutical medical goods and services. 1. Personal Health Care: "Personal health care" is comprised of therapeutic goods or services rendered to treat or prevent a specific disease or condition in a specific person.
Hospital Care:
Hospital care spending is defined to cover revenues received for all services provided by hospitals to patients. Thus, expenditures include revenues received to cover room and board, ancillary services such as operating room fees, services of resident physicians, inpatient pharmacy, hospital-based nursing home care, hospital-based home health care and fees for any other services billed by the hospital. 1977, 1982, 1987, 1992, 1997, and 2002 CSI (U.S. Bureau of the Census, 2005).
Home Health Care:
The home health component of the NHEA measures annual expenditures for medical care services delivered in the home by freestanding home health agencies (HHAs). NAICS 6216 defines home health care providers as private sector establishments primarily engaged in providing skilled nursing services in the home, along with a range of the following: personal care services; homemaker and companion services; physical therapy; medical social services; medications; medical equipment and supplies; counseling; 24-hour home care; occupation and vocational therapy; dietary and nutritional services; speech therapy; audiology; and high-tech care, such as intravenous therapy.
Prescription Drugs:
The category of prescription drugs includes retail sales of humanuse dosage-form drugs, biologicals and diagnostic products. The transactions to purchase prescription drugs occur in community pharmacies, grocery store pharmacies, mail-order establishments, and mass-merchandising establishments.
Other Non-Durable Medical Products:
The category of other non-durable medical products includes such items as rubber medical sundries, heating pads, bandages, and nonprescription drugs and analgesics. Nonprescription drugs sold over the counter include those marketed to the general public and those promoted to the medical professions and comprise products such as analgesics, and cough and allergy medications. Finally, medical sundries primarily include such items as surgical and medical instruments, surgical dressings, and diagnostic products such as needles and thermometers.
Durable Medical Products:
Expenditures in this category represent retail sales of items such as contact lenses, eyeglasses and other ophthalmic products, surgical and orthopedic products, equipment rental, oxygen and hearing aids. Durable products generally have a useful life of over three years whereas non-durable products last less than three years. 
Appendix B. Unit Root tests
Panel A reports t-statistics from Levin-Lin-Chu unit-root test for the optimal lag lengths of 0, 1, or 2, produced by the method described in Ng and Perron (2001) . The null hypothesis is that the variable has a unit root.***,**, and * indicate that unit-root is rejected at the 1%, 5%, and 10% levels, respectively. Panel B reports the % of states for which the variable's stationary is not rejected by a KPSS test in which the null hypothesis is that the variable is stationary. 
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